CTOs on the Move

Entegrion

www.entegrion.com

 
Entegrion is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Global Seven

Global Seven is a Franklin, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Theralogix

Theralogix is a Holmes, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ordaos Bio

Ordaos is a human-enabled, machine-driven drug design company.

Oregon Bioscience

Oregon Bioscience Association (@OregonBio) members are involved in cutting edge research and development of innovative health care, agricultural and environmental bio technologies. Our corporate members range from entrepreneurial start ups developing a first product to large multinationals. We also represent the state`s biotech research institutions, service providers to the industry and academic centers of learning. A unified voice for the Oregon bioscience community the Oregon Bio: * Represents the bioscience research to commercialization process * Helps to accelerate the growth of the biosciences industry in all parts of Oregon * Enhances the state`s bioscience business and research climate * Helps attract and retain bioscience talent and companies. * Vigorously works to improve the quality of the bioscience workforce * Partners with government at all levels to achieve its goals.

Impact Biomedicines

Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.